Dyne Therapeutics Stock Plunges 23% Despite Upcoming Long-Term Clinical Data
· rttnews.com
Dyne Therapeutics Inc. (DYN) shares are currently trading at $18.60, down $5.68, or 23.39 percent on Tuesday, despite the company announcing plans to present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 (DM1).
Dyne Therapeutics Inc. (DYN) shares are currently trading at $18.60, down $5.68, or 23.39 percent on Tuesday, despite the company announcing plans to present ad...